JX09

Small molecule

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (1)
Hypertension

Competitive landscape

6 other tracked programmes target this mechanism, 6 of them ahead of this one.

This drug's own stage for Hypertension: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
JX09: this drugPhase 1Small moleculeAldosterone synthase (CYP11B2)Partial signalNo reviewed efficacy summary in this indication
Aprocitentan (Tryvio)ApprovedSmall moleculeEndothelin receptor (ETA/ETB, dual)Reliable signal
NCT03541174: Week 4 sitting systolic blood pressure change: -15.26 vs -11.47 mmHg placebo for aprocitentan 12.5 mg; difference -3.79 mmHg (p=0.0042). For aprocitentan 25 mg: -15.20 vs -11.47 mmHg placebo; difference -3.73 mmHg (p=0.0046).
Baxdrostat (Baxfendy)ApprovedSmall moleculeAldosterone synthase (CYP11B2)Reliable signal
NCT06168409: Change in 24-hour ambulatory average SBP at week 12: -16.6 mmHg with baxdrostat vs -2.6 mmHg with placebo; between-group difference -14.0 mmHg (95% CI -17.2 to -10.8; p<0.0001).
NCT06034743: Change From Baseline in Seated Systolic Blood Pressure for 2 mg Baxdrostat (At Week 12): Double-Blind Treatment Period Weeks 0-12 Baxdrostat 2mg -15.7 mmHg (Standard Error 1) vs Double-Blind Treatment Period Weeks 0-12 Placebo -5.8 mmHg (Standard Error 1)
Propranolol (Inderal LA)ApprovedSmall moleculeBeta-1/beta-2 adrenergic receptorsnot yet gradedNo reviewed efficacy summary in this indication
AD-209Phase 3Small moleculeAngiotensin II type 1 receptor / L-type calcium channel / Na-Cl cotransporterPartial signal
NCT06348576: Week-8 sitting systolic blood pressure: non-inferiority and superiority vs telmisartan 40 mg confirmed in the full analysis set (published Phase III, 2026-02-20).
AGSAVIPhase 3Small moleculeAngiotensin II receptor / Calcium channel / Thiazide-like diureticPartial signalNo reviewed efficacy summary in this indication
Amlodipine / Valsartan / Rosuvastatin (CJ-30060)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasePartial signalNo reviewed efficacy summary in this indication
DWC202206 + DWC202207Phase 3Small molecule—Partial signalNo reviewed efficacy summary in this indication
Esaxerenone (Minnebro)Phase 3Small moleculeMineralocorticoid receptorPartial signal
NCT02722265: Change from baseline in sitting SBP/DBP, overall population (n=368): -16.1/-7.7 mmHg at week 12, -18.9/-9.9 mmHg at week 28, -23.1/-12.5 mmHg at week 52 (all 95% CI given); monotherapy subgroup (n=245): -16.3/-7.0 mmHg at week 12, -23.7/-12.3 mmHg at week 52
NCT02807987: Change from baseline in sitting SBP/DBP at end of treatment (Week 12), add-on-to-ARB/ACEI group (n=58): -17.8 mmHg SBP (95% CI -21.0 to -14.7), -8.1 mmHg DBP (95% CI -9.7 to -6.5), p<0.001
Fimasartan / Atorvastatin / Ezetimibe (BR1017)Phase 3Small moleculeAT1 receptor; NPC1L1; HMG-CoA reductasePartial signal
NCT05930028: Week 8 co-primary endpoints (full analysis set, 148 randomized): mean sitting systolic BP, fimasartan + atorvastatin/ezetimibe vs atorvastatin/ezetimibe, LS mean difference -7.26 mm Hg (95% CI -12.91 to -1.61), P = 0.0124; LDL-C percent change, fimasartan + atorvastatin/ezetimibe vs fimasartan, LS mean difference -58.02% (95% CI -66.03 to -50.02), P < 0.0001 (Hong et al., Clin Ther 2025).
Levamlodipine / Valsartan (SYH9056)Phase 3Small moleculeAngiotensin II type 1 receptor / L-type calcium channel (dual)Partial signal
NCT06771245: Blood-pressure lowering significantly superior to levamlodipine or valsartan monotherapy (sponsor, 2026-06-16).
LorundrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)Reliable signal
NCT06153693: Launch-HTN: change from baseline in automated office SBP at Week 6, lorundrostat 50 mg vs placebo: -16.9 mmHg absolute reduction; -9.1 mmHg placebo-adjusted reduction (p<0.0001)
NCT05769608: Placebo-adjusted change in 24-hour average ambulatory SBP at Week 12: -7.9 mmHg (lorundrostat 50 mg arm)
Olmesartan / Rosuvastatin (DWJ1276) (Olostar)Phase 3Small moleculeAngiotensin II receptor / HMG-CoA reductasePartial signal
NCT01764295: LDL-C percent change from baseline at week 8 (LS mean, SE): DWJ1276 (FDC) -52.3% (2.8%) vs olmesartan alone -0.6% (3.5%) vs rosuvastatin alone -46.9% (3.5%) vs placebo -3.2% (3.9%); FDC vs olmesartan difference -51.7% (95% CI -59.8% to -43.6%, P<0.0001).
Orforglipron (Foundayo)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
QR12000Phase 3Small moleculeAT1R; neprilysinPartial signalNo reviewed efficacy summary in this indication
Sacubitril / Valsartan (Entresto)Phase 3Small moleculeNeprilysin + Angiotensin II receptor (dual)Partial signal
NCT01599104: Mean sitting systolic BP reduction from baseline at week 8 vs olmesartan (LCZ696/Entresto, Japanese essential hypertension): sacubitril/valsartan 200mg difference -5.01 mmHg (95% CI -6.95 to -3.06, P<0.001 for noninferiority and superiority); 400mg difference -6.97 mmHg (95% CI -8.92 to -5.03, P<0.001).
NCT01593787: 43.8% (14/32) of patients reported at least one adverse event (mild severity; 0% serious AEs, 0% deaths); mean sitting SBP reduction 20.5±11.3 mmHg and mean sitting DBP reduction 8.3±6.3 mmHg from baseline to Week 8 (Total LCZ696 group, N=32); geometric mean UACR reduction 15.1%.
Safiglipron (HRS-7535)Phase 3Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
SAL0120Phase 3Small moleculeEndothelin receptor type A (ETA)not yet gradedNo reviewed efficacy summary in this indication
Valsartan / Amlodipine / Chlorthalidone (AJU-C52)Phase 3Small moleculeAngiotensin II receptor / Calcium channel / Thiazide-like diureticReliable signal
NCT06416865: Change in MSSBP from baseline to week 8: between-group difference of -10.99 (valsartan/amlodipine/chlorthalidone vs valsartan/amlodipine control)
VicadrostatPhase 3Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
ZilebesiranPhase 3RNA / oligonucleotideAngiotensinogen (AGT)Reliable signal
NCT04936035: Change From Baseline at Month 3 in 24-hour Mean SBP Assessed by ABPM (Baseline and Month 3): Placebo 6.8 millimeters of mercury (mmHg) ± 1.58 vs Zilebesiran 150 mg Q6M -7.3 millimeters of mercury (mmHg) ± 1.49 vs Zilebesiran 300 mg Q6M and Q3M -10.0 millimeters of mercury (mmHg) ± 1.05 vs Zilebesiran 600 mg Q6M -8.9 millimeters of mercury (mmHg) ± 1.52; p=<0.0001 (Placebo vs Zilebesiran 300 mg Q6M and Q3M), p=<0.0001 (Placebo vs Zilebesiran 600 mg Q6M)
HRS-9563Phase 2RNA / oligonucleotideAGT (angiotensinogen) mRNAnot yet gradedNo reviewed efficacy summary in this indication
IBI3016Phase 2RNA / oligonucleotideAngiotensinogen (AGT)not yet gradedNo reviewed efficacy summary in this indication
QCZ484Phase 2RNA / oligonucleotideAngiotensinogen (AGT)not yet gradedNo reviewed efficacy summary in this indication
QLS1410Phase 2Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
RTN-001Phase 2Small moleculePDE5not yet gradedNo reviewed efficacy summary in this indication
SAL0140Phase 2Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
TonlamarsenPhase 2RNA / oligonucleotideAngiotensinogen (AGT)Partial signal
NCT06864104: Co-primary 1, plasma angiotensinogen change to week 20: monthly tonlamarsen -67.2% vs single dose then placebo -23.0% (LS mean difference -44.1%, 97.5% CI -51.9% to -36.4%; P<0.0001), met. Co-primary 2, office systolic BP change to week 20: -6.7 vs -6.7 mm Hg (LS mean difference -0.1 mm Hg; P=0.97), missed.
NCT05314439: (-6% v. -79%, PBO v. 90 mg, p=0.001); median AGT reductions (-5% v. -86%, PBO v. 90 mg)
VB19055Phase 2Small moleculeAldosterone synthase (CYP11B2)not yet gradedNo reviewed efficacy summary in this indication
VCT220Phase 2Small moleculeGLP-1 receptornot yet gradedNo reviewed efficacy summary in this indication
BEBT-701Phase 1/2RNA / oligonucleotideAngiotensinogen (AGT) / PCSK9 (dual)not yet gradedNo reviewed efficacy summary in this indication
ADX-850Phase 1RNA / oligonucleotideAngiotensinogen (AGT)not yet gradedNo reviewed efficacy summary in this indication
Carvedilol (CKD-385)Phase 1Small moleculeBeta-adrenergic receptors (nonselective) and alpha-1 adrenergic receptor (antagonist)Partial signalNo reviewed efficacy summary in this indication
HJB647Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
HS-10522Phase 1Small molecule—not yet gradedNo reviewed efficacy summary in this indication
KK3910Phase 1Biologic (subtype unspecified)—not yet gradedNo reviewed efficacy summary in this indication
KN060Phase 1Monoclonal antibodyFactor XI/XIa (FXI/FXIa)not yet gradedNo reviewed efficacy summary in this indication
LivaloV
Phase 1(overall)
Small moleculeHMG-CoA reductase / Angiotensin II type 1 receptornot yet gradedNo reviewed efficacy summary in this indication
Long-Acting ANP Analog (LY3971297)Phase 1PeptideNatriuretic peptide receptor (NPR-A)not yet gradedNo reviewed efficacy summary in this indication
NurandociguatPhase 1Small moleculeSoluble guanylate cyclaseWeak signalNo reviewed efficacy summary in this indication
SHR-4658
Phase 1(overall)
Peptide—not yet gradedNo reviewed efficacy summary in this indication
C2402
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Candesartan / Amlodipine
—(overall)
Small moleculeAngiotensin II type 1 receptor / L-type calcium channelnot yet gradedNo reviewed efficacy summary in this indication
DehydraTECH-CBD
—(overall)
Small molecule—not yet gradedNo reviewed efficacy summary in this indication
Lercanidipine
—(overall)
Small moleculeL-type calcium channels (Cav1.2)not yet gradedNo reviewed efficacy summary in this indication
OLOMAX
—(overall)
Small moleculeAngiotensin II receptor / Calcium channel / HMG-CoA reductasenot yet gradedNo reviewed efficacy summary in this indication
Rosuampin
—(overall)
Small moleculeHMG-CoA reductase / Calcium channelnot yet gradedNo reviewed efficacy summary in this indication
N0877DiscontinuedSmall moleculeAngiotensin II receptor / Thiazide diureticnot yet gradedNo reviewed efficacy summary in this indication
SER-100DiscontinuedPeptideORL-1 (nociceptin opioid-like receptor)Weak signalFeatured results are safety only in this race

Upcoming events

No upcoming readouts on record for this asset.